Related Experiment Video
Updated: May 13, 2026

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase
Published on: June 24, 2025
Different Forms of Selenoprotein M Differentially Affect Aβ Aggregation and ROS Generation
Ping Chen1, Ruo-Ran Wang, Xiao-Jie Ma
1Shenzhen Key Laboratory of Marine Biotechnology and Ecology, Department of Marine Biology, Shenzhen University, Shenzhen 518060, China. liuqiong@szu.edu.cn.
Abstract:
Selenoprotein M (SelM), one of the executants of selenium in vivo, is highly expressed in human brain and most probably involved in antioxidation, neuroprotection, and intracellular calcium regulation, which are the key factors for preventing the onset and progression of Alzheimer's disease (AD). In this paper, human SelM was successfully overexpressed in human embryonic kidney cells HEK293T. Sodium selenite (Na(2)SeO(3) 0.5 μmol/L) increased the expression of full-length SelM and inhibited the expression of truncated SelM. The full-length SelM exhibited higher antioxidant activity than its selenocysteine-to-cysteine mutation form SelM', whereas the truncated SelM had an adverse effect that increased the oxidative stress level of cells. When β-amyloid (Aβ(42), an AD relevant peptide) was cotransfected with the empty expression vector, SelM, or SelM' under the induction of 0.5 μmol/L Na(2)SeO(3), the intracellular Aβ(42) aggregation rates were detected to be 57.9% ± 5.5%, or 22.3% ± 2.6%, or 26.3% ± 2.1%, respectively, showing the inhibitory effects on Aβ aggregation by the full-length SelM and SelM'. Meanwhile, the intumescentia of mitochondria caused by Aβ(42) transfection was significantly mitigated by the cotransfection of SelM or SelM' with Aβ(42) under the induction of 0.5 μmol/L Na(2)SeO(3). On the contrary, cotransfection of SelM and Aβ(42) without the induction of Na(2)SeO(3) increased Aβ(42) aggregation rate to 65.1% ± 3.2%, and it could not inhibit the Aβ-induced intumescent mitochondria. In conclusion, full-length SelM and SelM¢ might prevent Aβ aggregation by resisting oxidative stress generated during the formation of Aβ oligomers in cells.
Insights
Selenoprotein M (SelM) plays a crucial role in preventing Alzheimer's disease by reducing beta-amyloid aggregation and oxidative stress. Selenium supplementation enhances SelM's protective effects against neurodegeneration.
Area of Science:
- Biochemistry
- Neuroscience
- Cell Biology
Background:
- Selenoprotein M (SelM) is highly expressed in the human brain and implicated in neuroprotection.
- Alzheimer's disease (AD) is characterized by beta-amyloid (Aβ) aggregation and oxidative stress.
- Understanding SelM's role in AD pathogenesis is crucial for developing therapeutic strategies.
Purpose of the Study:
- To investigate the effect of Selenoprotein M (SelM) on beta-amyloid (Aβ) aggregation and oxidative stress in vitro.
- To determine the influence of sodium selenite on SelM expression and its functional activity.
- To evaluate the neuroprotective potential of full-length SelM and its variant (SelM') against Aβ-induced cellular damage.
Main Methods:
- Overexpression of human SelM in HEK293T cells.
- Treatment with sodium selenite (Na(2)SeO(3)) to modulate SelM expression.
- Cotransfection with Aβ(42) peptide to induce aggregation and cellular stress.
- Assessment of Aβ(42) aggregation rates and mitochondrial morphology.
Main Results:
- Sodium selenite promoted full-length SelM expression and inhibited truncated SelM.
- Full-length SelM and SelM' significantly inhibited Aβ(42) aggregation and mitigated Aβ-induced mitochondrial swelling.
- SelM' exhibited higher antioxidant activity than the mutated form.
- Absence of sodium selenite led to increased Aβ(42) aggregation and failed to protect mitochondria.
Conclusions:
- Full-length SelM and its variant SelM' demonstrate potential in preventing Aβ aggregation.
- Selenium supplementation enhances SelM's protective effects against oxidative stress and Aβ toxicity.
- SelM may serve as a therapeutic target for Alzheimer's disease by combating Aβ-induced cellular damage.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Protein Modifications in the RER
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal sequences.

